R
Richard J. Pietras
Researcher at University of California, Los Angeles
Publications - 109
Citations - 9295
Richard J. Pietras is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Estrogen receptor & Cancer. The author has an hindex of 45, co-authored 105 publications receiving 8960 citations. Previous affiliations of Richard J. Pietras include University of California, Berkeley & Monell Chemical Senses Center.
Papers
More filters
Journal ArticleDOI
Inhibitory effects of combinations of HER-2/ neu antibody and chemotherapeutic agents used for treatment of human breast cancers
Mark D. Pegram,Sheree Hsu,Gail D. Lewis,Richard J. Pietras,Malgorzata Beryt,Mark X. Sliwkowski,Daniel Coombs,Deborah L. Baly,Fairooz F. Kabbinavar,Dennis J. Slamon +9 more
TL;DR: The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.
Journal ArticleDOI
Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells
TL;DR: The relative quantity of these steroid receptors at the outer surfaces of cells from diverse tissues corresponds well with the capacity of a given cell to accumulate and retain oestrogen.
Journal Article
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Richard J. Pietras,M. Jane Arboleda,David M. Reese,Wongvipat N,Pegram,Lillian Ramos,Cornelia M. Gorman,Parker Mg,Mark X. Sliwkowski,Dennis J. Slamon +9 more
TL;DR: It is demonstrated that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen.
Journal ArticleDOI
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
Mark D. Pegram,Gottfried E. Konecny,Carminda O'Callaghan,Malgorzata Beryt,Richard J. Pietras,Dennis J. Slamon +5 more
TL;DR: Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials.
Journal Article
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
TL;DR: This phenomenon which the authors term receptor-enhanced chemosensitivity may provide a rationale for more selective targeting and exploitation of overexpressed growth factor receptors in cancer cells, thus leading to new strategies for clinical intervention.